These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22544264)

  • 1. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation.
    Bergamini G; Bell K; Shimamura S; Werner T; Cansfield A; Müller K; Perrin J; Rau C; Ellard K; Hopf C; Doce C; Leggate D; Mangano R; Mathieson T; O'Mahony A; Plavec I; Rharbaoui F; Reinhard F; Savitski MM; Ramsden N; Hirsch E; Drewes G; Rausch O; Bantscheff M; Neubauer G
    Nat Chem Biol; 2012 Apr; 8(6):576-82. PubMed ID: 22544264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kγ kinase activity is required for optimal T-cell activation and differentiation.
    Ladygina N; Gottipati S; Ngo K; Castro G; Ma JY; Banie H; Rao TS; Fung-Leung WP
    Eur J Immunol; 2013 Dec; 43(12):3183-96. PubMed ID: 24030559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases.
    Oka Y; Yabuuchi T; Oi T; Kuroda S; Fujii Y; Ohtake H; Inoue T; Wakahara S; Kimura K; Fujita K; Endo M; Taguchi K; Sekiguchi Y
    Bioorg Med Chem; 2013 Dec; 21(24):7578-83. PubMed ID: 24262886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing Small Molecule PI3Kγ Inhibitors: A Review of Structure-Based Methods and Computational Approaches.
    Yin X; Wang J; Ge M; Feng X; Zhang G
    J Med Chem; 2024 Jul; 67(13):10530-10547. PubMed ID: 38988222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
    Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
    J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils.
    Randis TM; Puri KD; Zhou H; Diacovo TG
    Eur J Immunol; 2008 May; 38(5):1215-24. PubMed ID: 18412166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
    Camps M; Rückle T; Ji H; Ardissone V; Rintelen F; Shaw J; Ferrandi C; Chabert C; Gillieron C; Françon B; Martin T; Gretener D; Perrin D; Leroy D; Vitte PA; Hirsch E; Wymann MP; Cirillo R; Schwarz MK; Rommel C
    Nat Med; 2005 Sep; 11(9):936-43. PubMed ID: 16127437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors.
    Zhu J; Li K; Yu L; Chen Y; Cai Y; Jin J; Hou T
    Med Res Rev; 2021 May; 41(3):1599-1621. PubMed ID: 33300614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
    Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3Kγ deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome.
    Berod L; Heinemann C; Heink S; Escher A; Stadelmann C; Drube S; Wetzker R; Norgauer J; Kamradt T
    Eur J Immunol; 2011 Mar; 41(3):833-44. PubMed ID: 21287545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).
    Mata G; Miles DH; Drew SL; Fournier J; Lawson KV; Mailyan AK; Sharif EU; Yan X; Beatty JW; Banuelos J; Chen J; Ginn E; Chen A; Gerrick KY; Pham AT; Wong K; Soni D; Dhanota P; Shaqfeh SG; Meleza C; Narasappa N; Singh H; Zhao X; Jin L; Schindler U; Walters MJ; Young SW; Walker NP; Leleti MR; Powers JP; Jeffrey JL
    J Med Chem; 2022 Jan; 65(2):1418-1444. PubMed ID: 34672584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.
    Nishihara M; Ogura H; Ueda N; Tsuruoka M; Kitabayashi C; Tsuji F; Aono H; Ishihara K; Huseby E; Betz UA; Murakami M; Hirano T
    Int Immunol; 2007 Jun; 19(6):695-702. PubMed ID: 17493959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response.
    Smirnova NF; Gayral S; Pedros C; Loirand G; Vaillant N; Malet N; Kassem S; Calise D; Goudounèche D; Wymann MP; Hirsch E; Gadeau AP; Martinez LO; Saoudi A; Laffargue M
    J Exp Med; 2014 Aug; 211(9):1779-92. PubMed ID: 25073791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
    Boyle DL; Kim HR; Topolewski K; Bartok B; Firestein GS
    J Pharmacol Exp Ther; 2014 Feb; 348(2):271-80. PubMed ID: 24244039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
    Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
    Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3Kγ drives priming and survival of autoreactive CD4(+) T cells during experimental autoimmune encephalomyelitis.
    Comerford I; Litchfield W; Kara E; McColl SR
    PLoS One; 2012; 7(9):e45095. PubMed ID: 23028778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner.
    Dagia NM; Agarwal G; Kamath DV; Chetrapal-Kunwar A; Gupte RD; Jadhav MG; Dadarkar SS; Trivedi J; Kulkarni-Almeida AA; Kharas F; Fonseca LC; Kumar S; Bhonde MR
    Am J Physiol Cell Physiol; 2010 Apr; 298(4):C929-41. PubMed ID: 20089935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Effects of a TANK-Binding Kinase 1 Inhibitor in Germinal Center-Driven Collagen-Induced Arthritis.
    Louis C; Ngo D; D'Silva DB; Hansen J; Phillipson L; Jousset H; Novello P; Segal D; Lawlor KE; Burns CJ; Wicks IP
    Arthritis Rheumatol; 2019 Jan; 71(1):50-62. PubMed ID: 30009417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.
    Jiang H; Abel PW; Toews ML; Deng C; Casale TB; Xie Y; Tu Y
    J Pharmacol Exp Ther; 2010 Sep; 334(3):703-9. PubMed ID: 20501633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis.
    Wang Y; Jia L; Wu CY
    Scand J Immunol; 2008 Oct; 68(4):383-90. PubMed ID: 18782267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.